BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 28133930)

  • 1. In vitro evaluation of Selective Inhibitors of Nuclear Export (SINE) drugs KPT-185 and KPT-335 against canine mammary carcinoma and transitional cell carcinoma tumor initiating cells.
    Grayton JE; Miller T; Wilson-Robles H
    Vet Comp Oncol; 2017 Dec; 15(4):1455-1467. PubMed ID: 28133930
    [No Abstract]   [Full Text] [Related]  

  • 2. Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma.
    Green AL; Ramkissoon SH; McCauley D; Jones K; Perry JA; Hsu JH; Ramkissoon LA; Maire CL; Hubbell-Engler B; Knoff DS; Shacham S; Ligon KL; Kung AL
    Neuro Oncol; 2015 May; 17(5):697-707. PubMed ID: 25366336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical evaluation of the novel, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study.
    London CA; Bernabe LF; Barnard S; Kisseberth WC; Borgatti A; Henson M; Wilson H; Jensen K; Ito D; Modiano JF; Bear MD; Pennell ML; Saint-Martin JR; McCauley D; Kauffman M; Shacham S
    PLoS One; 2014; 9(2):e87585. PubMed ID: 24503695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma.
    Sadowski AR; Gardner HL; Borgatti A; Wilson H; Vail DM; Lachowicz J; Manley C; Turner A; Klein MK; Waite A; Sahora A; London CA
    BMC Vet Res; 2018 Aug; 14(1):250. PubMed ID: 30143046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds.
    Crochiere M; Kashyap T; Kalid O; Shechter S; Klebanov B; Senapedis W; Saint-Martin JR; Landesman Y
    BMC Cancer; 2015 Nov; 15():910. PubMed ID: 26573568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia.
    Ranganathan P; Yu X; Na C; Santhanam R; Shacham S; Kauffman M; Walker A; Klisovic R; Blum W; Caligiuri M; Croce CM; Marcucci G; Garzon R
    Blood; 2012 Aug; 120(9):1765-73. PubMed ID: 22677130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds.
    Crochiere ML; Baloglu E; Klebanov B; Donovan S; Del Alamo D; Lee M; Kauffman M; Shacham S; Landesman Y
    Oncotarget; 2016 Jan; 7(2):1863-77. PubMed ID: 26654943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines.
    Breit MN; Kisseberth WC; Bear MD; Landesman Y; Kashyap T; McCauley D; Kauffman MG; Shacham S; London CA
    BMC Vet Res; 2014 Jul; 10():160. PubMed ID: 25022346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor.
    Subhash VV; Yeo MS; Wang L; Tan SH; Wong FY; Thuya WL; Tan WL; Peethala PC; Soe MY; Tan DSP; Padmanabhan N; Baloglu E; Shacham S; Tan P; Koeffler HP; Yong WP
    Sci Rep; 2018 Aug; 8(1):12248. PubMed ID: 30115935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth.
    Inoue H; Kauffman M; Shacham S; Landesman Y; Yang J; Evans CP; Weiss RH
    J Urol; 2013 Jun; 189(6):2317-26. PubMed ID: 23079374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma.
    Gandhi UH; Senapedis W; Baloglu E; Unger TJ; Chari A; Vogl D; Cornell RF
    Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):335-345. PubMed ID: 29610030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Nuclear Attack on Traumatic Brain Injury: Sequestration of Cell Death in the Nucleus.
    Tajiri N; De La Peña I; Acosta SA; Kaneko Y; Tamir S; Landesman Y; Carlson R; Shacham S; Borlongan CV
    CNS Neurosci Ther; 2016 Apr; 22(4):306-15. PubMed ID: 26842647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma.
    Zhang K; Wang M; Tamayo AT; Shacham S; Kauffman M; Lee J; Zhang L; Ou Z; Li C; Sun L; Ford RJ; Pham LV
    Exp Hematol; 2013 Jan; 41(1):67-78.e4. PubMed ID: 22986101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185.
    Tabe Y; Kojima K; Yamamoto S; Sekihara K; Matsushita H; Davis RE; Wang Z; Ma W; Ishizawa J; Kazuno S; Kauffman M; Shacham S; Fujimura T; Ueno T; Miida T; Andreeff M
    PLoS One; 2015; 10(9):e0137210. PubMed ID: 26340096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The selective inhibitor of nuclear export (SINE) verdinexor exhibits biologic activity against canine osteosarcoma cell lines.
    Breitbach JT; Louke DS; Tobin SJ; Watts MR; Davies AE; Fenger JM
    Vet Comp Oncol; 2021 Jun; 19(2):362-373. PubMed ID: 33438820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What is your diagnosis? Transitional cell carcinoma.
    Monibi FA; Tromblee TC
    J Am Vet Med Assoc; 2013 Jan; 242(2):157-9. PubMed ID: 23276088
    [No Abstract]   [Full Text] [Related]  

  • 17. CRM1 as a new therapeutic target for non-Hodgkin lymphoma.
    Han X; Wang J; Shen Y; Zhang N; Wang S; Yao J; Shi Y
    Leuk Res; 2015 Jan; 39(1):38-46. PubMed ID: 25466285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hedgehog signaling is activated in canine transitional cell carcinoma and contributes to cell proliferation and survival.
    Gustafson TL; Kitchell BE; Biller B
    Vet Comp Oncol; 2017 Mar; 15(1):174-183. PubMed ID: 25864514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human Exportin-1 is a Target for Combined Therapy of HIV and AIDS Related Lymphoma.
    Boons E; Vanstreels E; Jacquemyn M; Nogueira TC; Neggers JE; Vercruysse T; van den Oord J; Tamir S; Shacham S; Landesman Y; Snoeck R; Pannecouque C; Andrei G; Daelemans D
    EBioMedicine; 2015 Sep; 2(9):1102-13. PubMed ID: 26501108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin treatment of transitional cell carcinoma of the urinary bladder in dogs: 18 cases (1983-1993).
    Chun R; Knapp DW; Widmer WR; Glickman NW; DeNicola DB; Bonney PL
    J Am Vet Med Assoc; 1996 Nov; 209(9):1588-91. PubMed ID: 8899023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.